How to choose core outcome measurement sets for clinical trials: OMERACT 11 approves filter 2.0

Journal of Rheumatology

Volumn 41, Issue 5, 2014, Pages 1025-1030

  Boers, Maarten ^a   Kirwan, John R ^b   Gossec, Laure ^c   Conaghan, Philip G ^d   D'Agostino, Maria Antonietta ^e   Bingham, Clifton O ^f   Brooks, Peter M ^g   Landewé, Robert ^h   March, Lyn ⁱ   Simon, Lee ^j   Singh, Jasvinder A ^k   Strand, Vibeke ^l   Wells, George A ^m   Tugwell, Peter ^m  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d UNIVERSITY OF LEEDS   (United Kingdom)

^e HÔPITAL AMBROISE PARÉ   (France)

^f JOHNS HOPKINS UNIVERSITY   (United States)

^g UNIVERSITY OF MELBOURNE   (Australia)

^h ACADEMIC MEDICAL CENTER   (Netherlands)

ⁱ UNIVERSITY OF SYDNEY   (Australia)

^j SDG LLC   (United States)

^k UNIVERSITY OF ALABAMA   (United States)

^l STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m UNIVERSITY OF OTTAWA   (Canada)

more..

Author keywords

Clinical trials; Core outcome sets; Omeract filter; Outcome and process assessment

Indexed keywords

ARTICLE; BIOINFORMATICS; CLASSIFICATION ALGORITHM; CLINICAL ASSESSMENT TOOL; CLINICAL TRIAL; CONCEPTUAL FRAMEWORK; CONSENSUS DEVELOPMENT; CONSTRUCT VALIDITY; CONTENT VALIDITY; DATA ANALYSIS SOFTWARE; DIGITAL FILTERING; FACE VALIDITY; FEASIBILITY STUDY; HEALTH CARE COST; HEALTH SURVEY; HUMAN; INTERNATIONAL CLASSIFICATION OF FUNCTIONING, DISABILITY AND HEALTH; INTERNET; OUTCOME ASSESSMENT; OUTCOME MEASURES IN RHEUMATOLOGY 11; PATIENT REPORTED OUTCOME MEASUREMENT SYSTEM; PRIORITY JOURNAL; PROCESS DESIGN; PROCESS DEVELOPMENT; SYSTEM ANALYSIS; CLINICAL TRIAL (TOPIC); OBSERVATIONAL STUDY; RHEUMATIC DISEASES; RHEUMATOLOGY; STANDARDS; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; HUMANS; OBSERVATIONAL STUDY AS TOPIC; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); RHEUMATIC DISEASES; RHEUMATOLOGY;

EID: 84895444749     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.131314     Document Type: Article

References (26)

1. Tugwell P, Boers M, Brooks P, Simon L, Strand V, Idzerda L. OMERACT: An international initiative to improve outcome measurement in rheumatology. Trials 2007;8:38
2. Boers M, Brooks P, Strand V, Tugwell P. The OMERACT Filter for outcome measures in rheumatology. J Rheumatol 1998;25:198-9
3. Wells G, Anderson J, Beaton D, Bellamy N, Boers M, Bombardier C, et al. Minimal clinically important difference module: summary, recommendations, and research agenda. J Rheumatol 2001; 28:452-4 (Pubitemid 32165168)
4. Kirwan Jr. Minimum clinically important difference: the crock of gold at the end of the rainbow? J Rheumatol 2001;28:439-44 (Pubitemid 32165166)
5. Kirwan J, Heiberg T, Hewlett S, Hughes R, Kvien T, Ahlmen M, et al. Outcomes from the Patient Perspective Workshop at OMERACT 6. J Rheumatol 2003;30:868-72 (Pubitemid 36402790)
6. Kirwan JR, Minnock P, Adebajo A, Bresnihan B, Choy E, de Wit M, et al. Patient perspective: fatigue as a recommended patient centered outcome measure in rheumatoid arthritis. J Rheumatol 2007;34:1174-7 (Pubitemid 46774870)
7. Boers M, Tugwell P, Felson DT, van Riel PLCM, Kirwan JR, Edmonds JP, et al. World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. J Rheumatol Suppl. 1994 Sept;21:86-9 (Pubitemid 24285550)
8. Tugwell PS, Petersson IF, Boers M, Gossec L, Kirwan JR, Rader T, et al. Domains selection for patient-reported outcomes: current activities and options for future methods. J Rheumatol 2011;38:1702-10
9. Idzerda L, Rader T, Tugwell P, Boers M. Can we decide which outcomes should be measured in every clinical trial? A Scoping review of the existing conceptual frameworks and processes to develop core outcome sets. J Rheumatol 2013;40:986-93
10. International Classification of Diseases (ICD-10). World Health Organization, 1990. [Internet. Accessed January 17, 2014.] Available from: www.who.int/classifications/icd/en
11. International Classification of Functioning, Disability and Health (ICF). World Health Organization, 2001. [Internet. Accessed January 17, 2014.] Available from: www.who.int/classifications/icf/en
12. Patient-Reported Outcomes Measurement Information System (PROMIS), 2012. [Internet. Accessed January 17, 2014.] Available from: www.nihpromis.org
13. Williamson PR, Altman DG, Blazeby JM, Clarke M, Devane D, Gargon E, et al. Developing core outcome sets for clinical trials: issues to consider. Trials 2012;13:132
14. Boers M, Idzerda L, Kirwan JR, Beaton D, Escorpizo R, Boonen A, et al. Towards a generalized framework of core measurement areas in clinical trials: A position paper for OMERACT 11. J Rheumatol 2014;41:978-85
15. Kirwan JR, Fries JF, Hewlett SE, Osborne RH, Newman S, Ciciriello S, et al. Patient perspective workshop: moving towards OMERACT guidelines for choosing or developing instruments to measure patient-reported outcomes. J Rheumatol 2011;38:1711-5
16. Kirwan JR, Boers M, Hewlett S, Beaton D, Bingham CO, Choy E, et al. Updating the OMERACT Filter: core areas as a basis for defining core outcome sets. J Rheumatol 2014;41:994-9
17. Tugwell P, Boers M, D'Agostino M, Beaton D, Boonen A, Bingham CO, et al. Updating the OMERACT Filter: Implications of Filter 2.0 to select outcome instruments through assessment of content, face and construct validity. J Rheumatol 2014;41;1000-4
18. Wells GA, Beaton D, Tugwell P, Boers M, Kirwan JR, Bingham CO III, et al. Updating the OMERACT Filter: discrimination and feasibility. J Rheumatol 2014;41:1005-10
19. Auger C, Demers L, Swaine B. Making sense of pragmatic criteria for the selection of geriatric rehabilitation measurement tools. Arch Gerontol Geriatr 2006;43:65-83 (Pubitemid 43866961)
20. Kirwan JR, Bartlett SJ, Beaton D, Boers M, Bosworth A, Brooks PM, et al. Updating the OMERACT Filter: Implications for patient-reported outcomes. J Rheumatol 2014;41:1011-15
21. Guidance for industry - patient-reported outcome measures: Use in medical product development to support labeling claims. United States Department of Health and Human Services, Food and Drug Administration (FDA), 2009. [Internet. Accessed January 17, 2014.] Available from: www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ UCM193282.pdf
22. Frost MH, Reeve BB, Liepa AM, Stauffer JW, Hays RD. What is sufficient evidence for the reliability and validity of patient-reported outcome measures? Value Health 2007;10 Suppl 2:S94-S105
23. Sanderson TC, Hewlett SE, Flurey C, Dures E, Richards P, Kirwan Jr. The impact triad (severity, importance, self-management) as a method of enhancing measurement of personal life impact of rheumatic diseases. J Rheumatol 2011;38:191-4
24. D'Agostino MA, Boers M, Dougados M, Van Der Heijde D, Iagnocco A, Landewe RBM, et al. Updating the OMERACT Filter: Imaging and soluble biomarkers. J Rheumatol 2013;40:in press
25. Bernard HR. Research methods in anthropology: Qualitative and quantitative approaches. 4th ed. Lanham, MD: Alta Mira Press; 2006
26. Boers M, Kirwan JR, Wells G, Beaton D, Gosseo L, D'Agostino M, et al. Developing Core Outcome Measurement Sets for Clinical Trials: OMERACT Filter 2.0. J Clin Epidemiol 2014 (E-pub ahead of print)